Key result
Nesiritide improves hemodynamics and symptoms in decompensated heart failure, but lacks outcome data demonstrating superiority over conventional therapy.
Why the study?
Does nesiritide improve symptoms and hemodynamics in patients with decompensated heart failure?
Population
Patients with decompensated heart failure
Comparison
Nesiritide (intravenous) vs Conventional therapy
Design
Review
Authors
Loading...
May support rapid hemodynamic and symptom relief in acute HF; leaves open superiority on outcomes versus conventional therapy.
Does nesiritide improve symptoms and hemodynamics in patients with decompensated heart failure?
Nesiritide is an effective intravenous vasodilator that improves hemodynamics and symptoms in decompensated heart failure without requiring hemodynamic monitoring, though robust outcome data demonstrating superiority over conventional therapy are lacking.
Michael Militello (2002) conducted a review in Decompensated heart failure. Nesiritide vs. Conventional therapy was evaluated. Nesiritide improves hemodynamics and symptoms in decompensated heart failure, but lacks outcome data demonstrating superiority over conventional therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: